Clinical Resources: Buprenorphine & Trauma-Related Emotional Dysregulation
For Clinicians & Patients
This page collects resources for clinicians and patients exploring the potential role of buprenorphine in chronic emotional dysregulation and interpersonal instability that developed in the context of complex trauma.
These materials are educational and mechanism-focused. They are not formal treatment guidelines and do not replace clinical judgment.
Mechanistic Overview
The endogenous opioid system plays a central role in regulating emotional pain, attachment behavior, and stress responses. Research suggests that chronic trauma and early adversity can produce lasting changes in this system, including reduced baseline μ-opioid signaling and trauma-linked overactivation of the κ-opioid stress pathway.
Buprenorphine is the only available medication that combines partial μ-opioid agonism (supporting emotional pain relief and social connection) with κ-opioid antagonism (reducing dysphoria and stress-driven shutdown). This dual action makes it mechanistically well-suited for people whose core symptoms involve chronic emptiness, interpersonal instability, and distress intolerance.
For a detailed list of supporting papers, see the Research page.
Clinical Considerations
- Low-dose buprenorphine for emotional dysregulation typically uses sub-milligram doses — far below opioid use disorder treatment doses.
- The largest controlled trial used a mean dose of 0.44 mg/day in opioid-naïve patients with severe suicidal ideation.
- Opioid-naïve individuals may be very sensitive to buprenorphine. Starting at standard OUD initiation doses (2 mg+) may be excessive.
- Buprenorphine carries real risks including dependence, withdrawal on discontinuation, and dental effects with sublingual use. See the safety section for details.
- This is an off-label use. Prescribing decisions should be made collaboratively between clinician and patient with full informed consent.
Detailed Clinical Resources
The most comprehensive clinical materials I've developed — including a detailed guide for primary care clinicians and a quick reference card — live at bpd.fyi, a companion site covering the same mechanisms and treatment approach. The diagnostic framing there differs, but the clinical content is directly relevant to CPTSD presentations.
Status
This page is shared to invite thoughtful feedback from clinicians, researchers, and people with lived experience. It is a working document and will be revised as new evidence and clinical insight develop.
Contact
For questions, feedback, or discussion:
contact@cptsd.fyi